Plus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience

Reuters

Mar 26

Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience

Plus Therapeutics appointed Ron Andrews to its Board of Directors.
Andrews has more than 35 years of experience in diagnostics and molecular diagnostics, including leadership roles at Abbott Diagnostics, Roche Molecular Diagnostics, and LifeTechnologies/Thermo Fisher.
He previously served as CEO at Clarient and Oncocyte, and has held interim CEO and Executive Chairman roles supporting venture capital portfolio companies.
Andrews has been involved in more than USD 600.0 million of capitalization and more than USD 15.0 billion in exits during his career.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260730PRIMZONEFULLFEED9679003) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622854237"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622854237\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622854237?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622854237","market":"nz","top_or_hot":-1,"title":"Plus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Plus Therapeutics appointed Ron Andrews to its Board of Directors.\n        </li>\n<li>\n          Andrews has more than 35 years of experience in diagnostics and molecular diagnostics, including leadership roles at Abbott Diagnostics, Roche Molecular Diagnostics, and LifeTechnologies/Thermo Fisher.\n        </li>\n<li>\n          He previously served as CEO at Clarient and Oncocyte, and has held interim CEO and Executive Chairman roles supporting venture capital portfolio companies.\n        </li>\n<li>\n          Andrews has been involved in more than USD 600.0 million of capitalization and more than USD 15.0 billion in exits during his career.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260730PRIMZONEFULLFEED9679003) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Plus Therapeutics appointed Ron Andrews to its Board of Directors.\n        </li>\n<li>\n          Andrews has more than 35 years of experience in diagnostics and molecular diagnostics, including leadership roles at Abbott Diagnostics, Roche Molecular Diagnostics, and LifeTechnologies/Thermo Fisher.\n        </li>\n<li>\n          He previously served as CEO at Clarient and Oncocyte, and has held interim CEO and Executive Chairman roles supporting venture capital portfolio companies.\n        </li>\n<li>\n          Andrews has been involved in more than USD 600.0 million of capitalization and more than USD 15.0 billion in exits during his career.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260730PRIMZONEFULLFEED9679003) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLb3Nfbx:1","article_id":"2622854237","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622854237","pubTimestamp":1774524738,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"He previously served as CEO at Clarient and Oncocyte, and has held interim CEO and Executive Chairman roles supporting venture capital portfolio companies.Andrews has been involved in more than USD 600.0 million of capitalization and more than USD 15.0 billion in exits during his career.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","NEO":"NeoGenomics","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","PSTV":"Plus Therapeutics, Inc.","BK4112":"金融交易所和数据","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","ABT":"雅培","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4121":"生命科学工具和服务","NDAQ":"纳斯达克OMX交易所","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4139":"生物科技","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","IMDX":"Insight Molecular Diagnostics Inc.","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU2125909916.SGD":"Natixis Thematics Safety R/A SGD","TMO":"赛默飞世尔","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4535":"淡马锡持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","BK4504":"桥水持仓","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC"},"translate_title":"Plus Therapeutics任命Ron Andrews为董事会成员；Andrews拥有35年的诊断经验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":0.9,"TMO":0.9,"NEO":0.9,"NDAQ":0.9,"PSTV":0.9,"IMDX":0.9},"content_text":"Plus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience\n    \n\n\n          Plus Therapeutics appointed Ron Andrews to its Board of Directors.\n        \n\n          Andrews has more than 35 years of experience in diagnostics and molecular diagnostics, including leadership roles at Abbott Diagnostics, Roche Molecular Diagnostics, and LifeTechnologies/Thermo Fisher.\n        \n\n          He previously served as CEO at Clarient and Oncocyte, and has held interim CEO and Executive Chairman roles supporting venture capital portfolio companies.\n        \n\n          Andrews has been involved in more than USD 600.0 million of capitalization and more than USD 15.0 billion in exits during his career.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260730PRIMZONEFULLFEED9679003) on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}